David Badawi Sells 3,128 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,128 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $6.42, for a total transaction of $20,081.76. Following the transaction, the chief technology officer now directly owns 1,759,648 shares in the company, valued at approximately $11,296,940.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sight Sciences Trading Up 0.5 %

NASDAQ:SGHT opened at $6.19 on Thursday. The company has a quick ratio of 12.42, a current ratio of 13.01 and a debt-to-equity ratio of 0.31. The firm’s 50 day moving average is $6.07 and its two-hundred day moving average is $5.26. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $9.31.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The firm had revenue of $19.27 million for the quarter, compared to analysts’ expectations of $18.34 million. Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. On average, equities research analysts predict that Sight Sciences, Inc. will post -1.13 earnings per share for the current fiscal year.

Institutional Trading of Sight Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System purchased a new stake in Sight Sciences during the first quarter worth approximately $59,000. Tower Research Capital LLC TRC raised its stake in shares of Sight Sciences by 180.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock valued at $62,000 after acquiring an additional 7,764 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Sight Sciences by 51.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after acquiring an additional 9,106 shares in the last quarter. Federated Hermes Inc. boosted its position in Sight Sciences by 100.0% during the 3rd quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $202,000 after purchasing an additional 30,000 shares during the period. Finally, Panagora Asset Management Inc. increased its holdings in Sight Sciences by 198.1% in the 4th quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company’s stock valued at $305,000 after purchasing an additional 39,333 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on SGHT shares. Piper Sandler reiterated a “neutral” rating and issued a $6.00 price target (up from $5.00) on shares of Sight Sciences in a report on Friday, May 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $4.70.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.